<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04215510</url>
  </required_header>
  <id_info>
    <org_study_id>early-rNPC-RCT-01</org_study_id>
    <nct_id>NCT04215510</nct_id>
  </id_info>
  <brief_title>Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT</brief_title>
  <official_title>A Multicenter Randomized Controlled Trial for Comparing Endonasal Surgery and Radiation Therapy (IMRT) for T1-T2 Recurrent Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eye &amp; ENT Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Municipal Science and Technology Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eye &amp; ENT Hospital of Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter RCT to compare 3-year overall survival(OS) rate, progression free&#xD;
      survival(PFS),local progression free survival(LPFS),regional progression free&#xD;
      survival(RPFS),distant metastasis free survival(DMFS), and toxicities of endonasal endoscopic&#xD;
      surgery versus IMRT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Local and regional recurrence is a common cause of failure after primary radiotherapy for&#xD;
      nasopharyngeal carcinoma. Radiotherapy and surgery are the treatments of choice for recurrent&#xD;
      NPC. This study aims to compare 3 year overall survival(OS) rate of surgery versus IMRT.A&#xD;
      stratified-block randomized approach will be used to randomly assign patients into two&#xD;
      treatment groups after stratification according to N staging (N0 vs non-N0). Patients with&#xD;
      rNPC will be recruited and randomized into two groups in 1:1 ratio. The primary outcomes will&#xD;
      be 3 year overall survival(OS), the secondary outcome measures will be PFS,LPFS,RPFS,DMFS,and&#xD;
      toxicities.Assessment will be performed at baseline and during 3 years post-randomization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2027</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3 year Overall Survival (OS) rate</measure>
    <time_frame>From date of randomization until the date of death from any cause,through study completion,up to 3 years.</time_frame>
    <description>The proportion of patients who survived 3 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival(PFS)</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first，through study completion,up to 3 years.</time_frame>
    <description>the time from randomization to the first recording of disease progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local progression free survival(LPFS)</measure>
    <time_frame>From randomization to local failure or date of death from any cause,through study completion,up to 3 years.</time_frame>
    <description>the time from randomization to local failure or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional progression free survival(RPFS)</measure>
    <time_frame>From randomization to regional failure or date of death from any cause, through study completion,up to 3 years.</time_frame>
    <description>From randomization to regional failure or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis free survival(DMFS)</measure>
    <time_frame>From randomization to distant metastasis or date of death from any cause, through study completion,up to 3 years.</time_frame>
    <description>From randomization to distant metastasis or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicities</measure>
    <time_frame>From date of randomization until 3 years after randomization,through study completion,up to 3 years.</time_frame>
    <description>Using CTCAE Version5.0 to evaluate</description>
  </secondary_outcome>
  <other_outcome>
    <measure>quality of life(QoL): EORTC QLQ - H&amp;N35 questionaire</measure>
    <time_frame>From date of randomization until 3 years after randomization,through study completion,up to 3 years.</time_frame>
    <description>using European Organisation for Research and Treatment of Cancer quality of life questionaire（EORTC QLQ）- H&amp;N35，All of the scales and single-item measures range in score from 0 to 100. For all the scales and single-items a high score represents a high level of symptomatology or problems.</description>
  </other_outcome>
  <other_outcome>
    <measure>quality of life(QoL): EORTC QLQ - C30 questionaire</measure>
    <time_frame>From date of randomization until 3 years after randomization,through study completion,up to 3 years.</time_frame>
    <description>using European Organisation for Research and Treatment of Cancer quality of life questionaire（EORTC QLQ) - C30 version3.0. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">286</enrollment>
  <condition>Recurrent Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>endonasal endoscopic surgery group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>143 participants in group 1 will undergo endoscopic surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>radiation therapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>143 participants in group 2 will undergo radiation therapy(IMRT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>endonasal endoscopic surgery</intervention_name>
    <description>143 patients will undergo endonasal endoscopic surgery</description>
    <arm_group_label>endonasal endoscopic surgery group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy(IMRT)</intervention_name>
    <description>143 patients will undergo radiation therapy.</description>
    <arm_group_label>radiation therapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosed of recurrent nasopharyngeal carcinoma by pathology or imaging study;&#xD;
&#xD;
          2. Stage T1 or T2 according to AJCC 8th edition ;&#xD;
&#xD;
          3. Aged 18 to 70 years;&#xD;
&#xD;
          4. Without metastasis;&#xD;
&#xD;
          5. previously received 1 course of radiotherapy;&#xD;
&#xD;
          6. Without radiotherapy within 1 year, without local treatment for recurrent disease;&#xD;
&#xD;
          7. Surgical resectable and IMRT suitable;&#xD;
&#xD;
          8. If regional recurrence presented, regional lesion can be treated with local&#xD;
             treatments.&#xD;
&#xD;
          9. ECOG score 0 or 1;&#xD;
&#xD;
         10. Sufficient organ function;&#xD;
&#xD;
         11. Acceptable approach of contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Refuse to sign inform consent;&#xD;
&#xD;
          2. Radiation encephalopathy or leptomeningeal disease (LMD);&#xD;
&#xD;
          3. History of radioactive particle planting;&#xD;
&#xD;
          4. Have uncontrolled intercurrent illnesses which will interfere with the ability to&#xD;
             undergo therapy;&#xD;
&#xD;
          5. With prior malignancy (excluding adequately treated basal cell or squamous cell skin&#xD;
             cancer, in-situ cervical cancer );&#xD;
&#xD;
          6. Any contradiction to surgery;&#xD;
&#xD;
          7. Have any co-existing condition that would preclude full compliance or safety with the&#xD;
             study;&#xD;
&#xD;
          8. Presence of a significant neurological or psychiatric disease, including dementia and&#xD;
             seizures;&#xD;
&#xD;
          9. Uncontrolled infectious diseases;&#xD;
&#xD;
         10. Female patients who are at pregnancy or lactation.&#xD;
&#xD;
         11. Without personal freedom or independent civil capacity.&#xD;
&#xD;
         12. With serious autoimmune disease.&#xD;
&#xD;
         13. Participants of other interventional clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongmeng Yu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eye&amp;ENT Hospital,Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaole Song, MD</last_name>
    <phone>+86 15821388769</phone>
    <email>jxfxsxl@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhihui Pang</last_name>
    <phone>+86 18818211894</phone>
    <email>pangzhihui1229@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Desheng Wang, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Haichun Lai, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Desheng Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jing Ye, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jing Ye</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai cancer center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Lin Kong, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Jiyi Hu, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Lin Kong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 2, 2019</study_first_submitted>
  <study_first_submitted_qc>December 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>February 20, 2021</last_update_submitted>
  <last_update_submitted_qc>February 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Eye &amp; ENT Hospital of Fudan University</investigator_affiliation>
    <investigator_full_name>Hongmeng Yu</investigator_full_name>
    <investigator_title>MD,PhD</investigator_title>
  </responsible_party>
  <keyword>endonasal endoscopic surgery</keyword>
  <keyword>radiation therapy</keyword>
  <keyword>nasopharyngeal carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

